NEWTOWN, Pa., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Forian Inc. (Nasdaq: FORA) announces that Max Wygod, Chief Executive Officer and Executive Chairman, and Mike Vesey, Chief Financial Officer, will attend ROTH MKM’s 13th annual Technology Event, which will be held on November 19th – 20th, 2024, at the Hard Rock Hotel in New York City.
This year’s event will consist of 1-on-1 / small group meetings with over 70 innovative growth companies spanning the technology landscape.
The format will provide investors with the opportunity to hear from and meet executive management from public and pre-public companies across various Technology sub-sectors. Each meeting will consist of a 40-minute session between management and investors, allowing for extensive interaction and in-depth insights into each company.
For more information or interested in meeting, please visit https://www.roth.com/NYtechday2024.
About ROTH MKM:
ROTH MKM is a relationship-driven investment bank focused on serving growth companies and their investors. Our full-service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory and corporate access. Headquartered in Newport Beach, California, ROTH MKM is a privately held, employee-owned organization and maintains offices throughout the U.S. For more information, please visit www.roth.com.
About FORIAN INC.
Forian provides a unique suite of data management capabilities and proprietary information and analytics solutions to optimize and measure operational, clinical and financial performance for customers within the traditional and emerging life sciences and healthcare payer and provider segments. For more information, please visit Forian’s website at www.forian.com.
Media and Investor Contact:
forian.com/investors
This email address is being protected from spambots. You need JavaScript enabled to view it.
267-225-6263
Last Trade: | US$2.05 |
Daily Change: | -0.05 -2.38 |
Daily Volume: | 47,879 |
Market Cap: | US$63.780M |
November 13, 2024 August 14, 2024 November 09, 2023 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB